A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Genentech

ClinicalTrials.gov Identifier:

NCT00281697

First received: January 23, 2006

Last updated: February 15, 2013

Last verified: February 2013

History of Changes

Results First Received: August 23, 2012

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Investigator); Primary Purpose: Treatment
Condition:	Metastatic Breast Cancer
Interventions:	Drug: Bevacizumab Drug: Placebo Drug: Standard chemotherapy

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Standard Chemotherapy + Bevacizumab	Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.
Standard Chemotherapy + Placebo	Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.

Participant Flow: Overall Study

	Standard Chemotherapy + Bevacizumab	Standard Chemotherapy + Placebo
STARTED	459	225
COMPLETED	58	28
NOT COMPLETED	401	197
> 60 days since last dose of study drug	4	4
Adverse Event	54	15
Death	8	3
Disease progression	279	149
Not specified	5	6
Physician's decision to withdraw	15	12
Subject/guardian's decision to withdraw	33	6
Did not receive study drug	3	2

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Standard Chemotherapy + Bevacizumab	Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.
Standard Chemotherapy + Placebo	Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.
Total	Total of all reporting groups

Baseline Measures

	Standard Chemotherapy + Bevacizumab	Standard Chemotherapy + Placebo	Total
Number of Participants [units: participants]	459	225	684
Age [units: years] Mean ± Standard Deviation	55.6 ± 11.0	55.0 ± 11.2	55.4 ± 11.1
Gender [units: participants]
Female	457	225	682
Male	2	0	2

Outcome Measures

Show All Outcome Measures

1. Primary:

Progression-free Survival [ Time Frame: Baseline to data cut-off (up to 3 years, 2 months) ]

Hide Outcome Measure 1

Measure Type	Primary
Measure Title	Progression-free Survival
Measure Description	PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.
Time Frame	Baseline to data cut-off (up to 3 years, 2 months)
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent-to-treat population: All patients without treated brain metastasis who were randomized, regardless of whether they received any study treatment.

Reporting Groups

	Description
Standard Chemotherapy + Bevacizumab	Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.
Standard Chemotherapy + Placebo	Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.

Measured Values

	Standard Chemotherapy + Bevacizumab	Standard Chemotherapy + Placebo
Number of Participants Analyzed [units: participants]	459	225
Progression-free Survival [units: Months] Median ( 95% Confidence Interval )	7.2 ( 6.5 to 7.6 )	5.1 ( 4.1 to 6.0 )

No statistical analysis provided for Progression-free Survival

2. Secondary:

Progression-free Survival Within Individual Standard Chemotherapy Cohorts (Taxanes, Gemcitabine, Capecitabine, and Vinorelbine) [ Time Frame: Baseline to data cut-off (up to 3 years, 2 months) ]

Show Outcome Measure 2

3. Secondary:

Overall Survival [ Time Frame: Baseline to data cut-off (up to 3 years, 2 months) ]

Show Outcome Measure 3

4. Secondary:

One-year Survival [ Time Frame: Baseline to data cut-off (up to 3 years, 2 months) ]

Show Outcome Measure 4

5. Secondary:

Objective Response [ Time Frame: Baseline to data cut-off (up to 3 years, 2 months) ]

Show Outcome Measure 5

6. Secondary:

Duration of Objective Response [ Time Frame: Baseline to data cut-off (up to 3 years, 2 months) ]

Show Outcome Measure 6

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Medical Communications
Organization: Genentech, Inc.
phone: 800 821-8590

No publications provided

Responsible Party:	Genentech
ClinicalTrials.gov Identifier:	NCT00281697 History of Changes
Other Study ID Numbers:	AVF3693g
Study First Received:	January 23, 2006
Results First Received:	August 23, 2012
Last Updated:	February 15, 2013
Health Authority:	United States: Food and Drug Administration

To Top